For the Inventor, By the Inventor

Enter assignee name

Horsham, PA, United States of America

Cell Pathways

USPTO Granted Patents = 75

% Expired Patents = 13.3

Forward Citations = 807

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Rifat Pamukcu (67 out of 74 patents)

Gary A Piazza (54 out of 58 patents)

Gerhard J Sperl (22 out of 24 patents)

4. Paul Gross (17 out of 19 patents)

5. Klaus Brendel (16 out of 21 patents)

6. W Joseph Thompson (7 out of 8 patents)

7. Kerstin B Menander (6 out of 8 patents)

8. Han Li (4 out of 15 patents)

9. Li Liu (3 out of 3 patents)

10. Ulrich Ixkes (3 out of 3 patents)

11. Xiaojing Michael Wang (2 out of 12 patents)

12. Hector W Alila (2 out of 4 patents)

13. Keith A Earle (2 out of 3 patents)

14. Clark M Whitehead (2 out of 2 patents)

15. Mark Jeffrey Mayle (2 out of 2 patents)

Core Competencies:

Neoplasia

Cancer Treatment

Renal Cell Carcinoma

Precancerous Lesions

Pharmaceutical Compositions

Vinca Alkaloids

Isoquinoline Derivatives

Benzimidazole Derivatives

Purin-6-Ones

Phenyl Quinazolinone

Paclitaxel Derivatives

Indole Derivatives

75 patents: Sort by Forward Citations

1. 6569638 - Method for screening compounds for the treatment of neoplasia (2003-05-27),

2. 6562830 - Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives (2003-05-13),

3. 6555547 - Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative (2003-04-29),

4. 6538029 - Methods for treatment of renal cell carcinoma (2003-03-25),

5. 6500610 - Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds (2002-12-31),

6. 6486158 - [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia (2002-11-26),

7. 6486155 - Method of inhibiting neoplastic cells with isoquinoline derivatives (2002-11-26),

8. 6479520 - Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives (2002-11-12),

9. 6479493 - Methods for treatment of type I diabetes (2002-11-12),

10. 6472420 - Method for treating a patient with neoplasia by treatment with a paclitaxel derivative (2002-10-29),

11. 6465494 - Methods for treatment of cystic fibrosis (2002-10-15),

12. 6455703 - 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia (2002-09-24),

13. 6440981 - Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones (2002-08-27),

14. 6432950 - Method for inhibiting neoplastic cells and related conditions by exposure to benzothienopyrimidine derivatives (2002-08-13),

15. 6420410 - Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones (2002-07-16),

Cell Pathways is a biotechnology company specializing in innovative research and development of cell-based therapies. With a focus on regenerative medicine, Cell Pathways aims to revolutionize healthcare by harnessing the power of stem cells and advanced gene therapies. Our multidisciplinary team of experts is dedicated to pushing the boundaries of science to improve and extend the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

75 Patents

#4 in Horsham, PA

#185 in Pennsylvania

#4,896 in US

#9,985 in the World

Horsham, PA, United States of America

Cell Pathways

Forward Citations = 807

22 inventors:

Rifat Pamukcu (67 out of 74 patents)

Gary A Piazza (54 out of 58 patents)

Gerhard J Sperl (22 out of 24 patents)

4. Paul Gross (17 out of 19 patents)

5. Klaus Brendel (16 out of 21 patents)

Please report any incorrect information to [email protected]

Loading…